CTP synthase (CTPS) is a metabolic enzyme that catalyzes CTP biosynthesis from UTP, ATP, and glutamine, an essential step for DNA and RNA synthesis during cell proliferation. 9, 10 In the present study, we found that CTPS1 was induced by PDGF-BB in primary cultured proliferating SMCs in vitro and neointimal SMCs after vascular injury in vivo. Blocking CTPS function suppressed SMC proliferation and neointima formation, with sustained re-endothelialization in injured vessels. Our study identified CTPS1 as a novel target for developing antineointima drugs that are SMC sensitive but have little side effect on re-endothelialization during vascular repair.
N eointimal hyperplasia is one of the major obstacles limiting the long-term clinical efficiency of cardiovascular intervention, including angioplasty, bypass, and transplantation arteriopathy. 1 Neointima formation also contributes to the development and progression of several proliferative cardiovascular diseases such as hypertension and diabetic vascular complications. 2 Under pathological conditions, vascular injury causes denudation of endothelial layer, which triggers a series of acute and chronic inflammatory responses characterized by the production of various different growth factors or inflammatory cytokines. 3, 4 Media layer smooth muscle cell (SMC) proliferation and migration in response to injury-induced factors, such as platelet-derived growth factor-BB (PDGF-BB), are essential events contributing to subsequent neointimal thickening, 5, 6 which eventually leads to vessel narrowing. Re-endothelialization halts neointima formation and initiates the successful vascular repair. 7, 8 However, currently available antineointimal drugs indiscriminately block the proliferation of both SMCs and ECs, leading to impaired re-endothelialization and prolonged wound healing process. Therefore, it is critical to develop a novel antiproliferation strategy that is SMC sensitive.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

CTPS1 Was Upregulated in Cultured SMCs In Vitro and Neointimal SMCs In Vivo
It is well established that CTPS is involved in the proliferation of various different cells. [11] [12] [13] Although 2 different CTPS isotypes (CTPS1 and CTPS2) are identified in mammals, we found that CTPS1, but not CTPS2, was markedly upregulated in SMCs by PDGF-BB ( Figure 1A-1C and Figure I in the online-only Data Supplement). PDGF-BB is a well-known SMC mitogen that induces SMC proliferation and neointima formation after vascular injury. 14 PDGF-BB-mediated cell proliferation was confirmed by the upregulation of proliferating cell nuclear antigen (PCNA; Figure 1B and1C ). Because SMC proliferation is one of the major events in neointima formation under pathological conditions, 15 we examined CTPS1 expression in rat carotid arteries undergoing vascular remodeling after balloon injury. As shown in Figure 1D , CTPS1 was expressed at a low level in the media SMCs but was highly induced in neointimal SMCs. A low level of CTPS1 expression was also observed in ECs. Quantitative analysis showed that CTPS1 was significantly upregulated as early as 1 day after vascular injury. The expression was gradually increased during neointimal formation ( Figure 1E and 1F). PCNA expression correlated with the CTPS1 expression ( Figure 1F ).
Blocking CTPS Activity Inhibited SMC Proliferation
To determine whether CTPS1 plays a role in SMC proliferation, we blocked CTPS activity using cyclopentenyl cytosine Figure 1 . CTP synthase (CTPS) 1 was upregulated in proliferative smooth muscle cells (SMCs) both in vitro and in vivo. A, CTPS1 mRNA expression was upregulated by platelet-derived growth factor (PDGF)-BB in proliferating SMCs. B, CTPS1 and proliferating cell nuclear antigen (PCNA) protein expression was induced by PDGF-BB in SMCs. C, Quantification of CTPS1 and PCNA protein expression shown in B by normalizing to α-tubulin. D, CTPS1 was expressed in neointima SMCs after vascular injury as shown by immunohistochemistry staining. E, Time-dependent protein expression of CTPS1 and PCNA in rat carotid arteries after injury. F, Quantification of CTPS1 and PCNA protein expression shown in E by normalizing to α-tubulin. *P<0.05, **P<0.01, ***P<0.001 (n=3).
(CPEC), an effective and specific inhibitor for CTPS. 16, 17 As shown in Figure 2A , blockade of CTPS activity significantly suppressed SMC proliferation in a dose-dependent manner. CPEC treatment also dramatically suppressed PCNA expression ( Figure 2B and 2C). To confirm the specificity of CTPS1 function, we blocked CTPS1 expression by small hairpin RNA (shRNA) and found that knockdown of CTPS1 ( Figure 2E and 2F) effectively suppressed PDGF-BB-induced SMC proliferation ( Figure 2D ). CTPS1 shRNA seemed to inhibit vehicletreated SMC growth as well ( Figure 2D ). Consistently, CTPS1 knockdown also inhibited PCNA expression ( Figure 2E and 2F), further demonstrating the essential role of CTPS1 in SMC proliferation.
Blockade of CTPS1 Activity or Expression Did Not Induce SMC Apoptosis But Impaired Cell Cycle Progression
Because CPEC is a chemical with potential cytotoxicity, we sought to determine whether CPEC inhibited SMC proliferation through a nonspecific toxic effect. Apoptosis analysis using propidium iodide/annexin V double staining and flow cytometry indicated that 24-hour treatment with 500 nmol/L CPEC (the highest dosage used in this study) did not induce SMC apoptosis, comparable with the treatment with vehicle ( Figure 3A) . The serum-starved cells were used as a positive control, which caused a significant cell apoptosis (30.86%; Figure 3A ). However, CPEC treatment or CTPS1 knockdown significantly blocked cell cycle progression, as indicated by the accumulation of cells in G0/G1 phase ( Figure 3B and 3C). It seemed that CPEC treatment ( Figure 3D and 3E) or CTPS1 knockdown by shRNA ( Figure 3F and 3G) dramatically inhibited the activation of cell cycle regulator cyclin-dependent kinase 1 as evidenced by suppression of its phosphorylation at T161.
CTPS1 Played an Essential Role in Injury-Induced Vascular Remodeling
Because CTPS1 played an essential role in SMC proliferation in vitro and was induced in neointima SMCs after balloon injury, we hypothesized that CTPS1 plays an important role in injury-induced neointima formation in vivo. To test this hypothesis, we injured rat carotid arteries with balloon catheter to induce neointima formation and administered CPEC via mini-osmotic pumps to block CTPS1 activity. As expected, a thick layer of neointima was formed 14 days after injury. However, the neointima was dramatically blocked by a low dosage (1 mg/kg body weight per day) and completely blocked by a higher dosage of CPEC (2 mg/kg body weight per day; Figure 4A and 4B). The PCNA expression was also dramatically blocked by the low dosage of CPEC and completely blocked by the higher dosage of CPEC ( Figure 4C ). To confirm the specificity of CTPS1 function, we knocked down CTPS1 using adenoviral-mediated shRNA delivery in injured arteries. As shown in Figure 4D and 4F, CTPS1 shRNA dramatically blocked neointima formation ( Figure 4D and 4F) and PCNA expression in neointima SMCs ( Figure 4E ). To determine whether CPEC had a toxic effect on neointima SMCs, the in vivo cell apoptosis was detected by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Consistent with the in vitro results ( Figure 3A ), no apoptotic cells were observed in the vessel sections from CPEC-treated arteries even with the higher dosage of CPEC (2 mg/kg body weight per day; Figure 4G ). These results demonstrate that CTPS1 is a novel drug target for blocking injury-induced neointima formation/vascular remodeling.
Blockade of CTPS1 Activity or Expression Impacted ECs Differently From SMCs In Vitro and Sustained Re-Endothelialization In Vivo
Re-endothelialization is an essential step toward successful vascular repair in injury-induced vessel wall remodeling. Current antineointima strategies targeting genes or signaling pathways for SMC proliferation also block re-endothelialization and cause thrombosis as a side effect. 18, 19 It is important, therefore, to identify drug targets that do not block re-endothelialization. Because CTPS1 played an important role in neointima formation, we sought to determine whether blocking CTPS1 activity or expression has any effect on ECs. We first tested whether CPEC has any effect on EC proliferation in vitro. As shown in Figure 5A , EC proliferation was not affected by low dosages of CPEC treatments (≤20 nmol/L), in which SMC proliferation was attenuated, indicating that SMCs are more sensitive than ECs to CPEC challenge. A higher dosage of CPEC (500 nmol/L) significantly blocked the proliferation of both SMCs and ECs, indicating that a certain level of CTPS activity is required for EC proliferation. Indeed, CTPS1 was induced in ECs by different growth stimuli ( Figure II in the online-only Data Supplement). Interestingly, addition of extracellular cytidine restored EC, but not SMC, proliferation blocked by the high dosage of CPEC ( Figure 5A ), suggesting that SMCs and ECs may use different pathways to regulate their CTP synthesis and consequently their proliferation. Although cytidine is important for EC proliferation, abundant CTP alone seemed not to be able to stimulate either EC or SMC proliferation ( Figure III in the online-only Data Supplement), probably because the proliferation also requires many other factors including cyclindependent kinase activity.
Paclitaxel (Taxus), one of the drugs currently used for coating stents and treating coronary artery diseases, effectively blocks SMC proliferation and restenosis after angioplasty. However, paclitaxel suppressed both EC and SMC proliferation at a lower (20 nmol/L) or higher dosage (500 nmol/L; Figure 5B ), consistent with previous reports. Unlike blockade of CTPS1, paclitaxel-mediated inhibitory effect could not be restored by cytidine ( Figure 5B ). In addition, ECs seemed to be more sensitive to paclitaxel than SMCs. These results suggest that blocking CTPS1 may be a better strategy to block restenosis during cardiovascular intervention.
To determine whether CTPS1 plays a role in re-endothelialization during vascular remodeling, we systematically administered CPEC via osmotic pump into rats with balloon injury. As shown in Figure 5C , a weak re-endothelialization was found in the carotid arteries after 2 months of vascular injury as indicated by the expression of EC marker CD31, suggesting a slow and weak proliferation of ECs during the natural vascular repair process. However, CPEC administration (1 mg/kg per day) induced a strong re-endothelialization 14 days after the injury while significantly inhibiting the neointima formation compared with salinetreated arteries ( Figure 5C , the last 2 images). Quantification of the re-endothelialization areas in Evans blue-stained vessel ( Figure 5D ) showed that CPEC treatment increased the re-endothelialization area to 66% of the injured vessels compared with 24% in saline-treated vessels ( Figure 5E ). Consistently, PCNA was strongly expressed in CD31-positive cells ( Figure 5F ), suggesting that CPEC treatment preserved or promoted EC proliferation in injured vessel. The specificity of CPEC effect on CTPS1 activity was confirmed by adenovirus-mediated CTPS1 shRNA. As shown in Figure 5G , knockdown of CTPS1 induced reendothelialization while blocking neointima formation, similar to the effect observed in CPEC treatment ( Figure 5C ). To further establish CTPS function in re-endothelialization after vascular injury, we observed the endothelial denudation and re-endothelialization in a different model (ie, mouse wire injury model). The re-endothelialization was observed in intact carotid arteries using Evans blue staining of the injured areas. Systematic administration of CPEC was achieved via osmotic pump (1 mg/kg per day). As shown in Figure 5H and 5I, re-endothelialization in mouse arteries occurred rapidly after injury. Five days after injury, re-endothelialization was completed, consistent with the previous reports. 20 CEPC treatment did not delay the rapid re-endothelialization. Importantly, at 3 days after the injury, CPEC-treated arteries seemed to have a larger area that was re-endothelialized compared with the saline-treated arteries ( Figure 5H and 5I) , indicating that CPEC accelerated the reendothelialization process. Taken together, these data indicate that blockade of CTPS activity or expression sustains EC proliferation, which may improve the re-endothelialization during vascular repair after injury.
Induction of CTP Synthesis Salvage Pathway Sustained the Proliferation of CPEC-Treated ECs In Vitro and Re-Endothelialization of the Injured Vessel In Vivo
Because ECs, but not SMCs, used extracellular cytidine to restore cell proliferation in the high dosage of CPEC treatment ( Figure 5A ), we sought to determine the alternative pathway that preserved the EC proliferation. CTPS synthesizes CTP via a so-called neosynthesis pathway using UTP, ATP, and glutamine as substrates. 21 However, there is a salvage pathway that uses cytidine as substrate when the neosynthesis pathway is deficient. 22, 23 Cytidine is used by several salvage pathway enzymes, including uridine-cytidine kinase (UCK1/2), cytidine monophosphate kinase (CMPK), and nucleoside-diphosphate kinase A and B (NME1 and NME2). 24, 25 As shown in Figure 6A , CPEC significantly induced mRNA expression of all the salvage pathway enzymes in the presence of cytidine in ECs, but not SMCs, suggesting that ECs, but not SMCs, are able to use the salvage pathway when CTPS pathway is blocked. Because NME1/2 play similar roles in the salvage pathway as CTPS in the neosynthesis pathway, and the end product of both NMEs and CTPS is CTP, NME1 or NME2 is most likely to be responsible for preserving the EC proliferation when CTPS was blocked. CPEC seemed to induce NEM2 expression more than NME1 in proliferative ECs ( Figure 6A) . Interestingly, PDGF-BB, vascular endothelial growth factor, or CPEC treatment alone did not upregulate the expression of NME1 or NME2 in ECs. However, combination of CPEC with either one of the growth factors (vascular endothelial growth factor or PDGF) in the presence of cytidine dramatically upregulated the NME, especially the NME2 expression ( Figure 6B and 6C) . These data suggest that an elevated level of the salvage pathway activities may be required for EC proliferation when the neosynthesis pathway is blocked.
Although both NME1 and NME2 are important for the NME activity in the salvage CTP synthesis pathway, 26 NME2 overexpression in SMCs ( Figure IV in the online-only Data Supplement) displayed a stronger activity than NME1 in using cytidine to restore CPEC-attenuated proliferation ( Figure V in the online-only Data Supplement). Consistently, knockdown of NME2 by adenovirus-expressed shRNA dramatically decreased cytidine-mediated restoration of EC proliferation that was blocked by a high dosage of CPEC ( Figure 6D ), demonstrating an essential role of NME2 in using cytidine to mediate EC proliferation. These results indicate that NME2 protects ECs from CPEC challenge by using cytidine as the substrate for CTP salvage synthesis pathway.
To test whether NME2 is involved in the re-endothelialization in vivo, we examined whether NME2 is expressed in arteries undergoing vascular repair after injury-induced vascular remodeling. As shown in Figure 6E and 6F, NME2 was expressed mainly in ECs, but not SMCs, in arteries. CPEC treatment induced a strong NME2 expression in ECs of the arteries with enhanced re-endothelialization ( Figure 6E versus Figure 5C and 5D), suggesting that NME2 may be critical for the re-endothelialization. To test this, we knocked down both CTPS1 and NME2 using shRNAs in injured rat carotid arteries. As shown in Figure 6G and 6H, knockdown of CTPS1 and NME2 simultaneously suppressed re-endothelialization as indicated by the loss of CD31-positive cells compared with CTPS1 knockdown alone. These data demonstrate that NME2 is essential for the proliferation of ECs when the cells are treated with CPEC, which facilitates the re-endothelialization in vivo.
Discussion
Using both pharmacological and loss-of-function approaches, we demonstrate that targeting CTPS1 can effectively suppress neointima formation after vascular injury. Importantly, low dosages of CPEC inhibit SMC, but not EC growth, suggesting that ECs are less sensitive to CPEC treatment. High dosage of CPEC suppresses both SMC and EC proliferation, indicating that a relatively low level of CTPS activity is required for EC proliferation. Interestingly, the inhibitory effect of high dosage of CPEC can be reversed by addition of cytidine, a substrate for CTP synthesis salvage pathway, indicating that salvage pathway is important for EC proliferation. Thus, our study demonstrates for the first time that SMCs and ECs have a distinct preference in using CTP synthesis pathways for their proliferation. SMCs seem to mainly use CTPS-mediated de novo synthesis pathway. Although CTPS-mediated pathway is much less essential for ECs, ECs seem to use both the de novo and the salvage pathways to synthesize CTP.
We have identified a novel strategy to potentially overcome a long-standing medical challenge, that is, the impaired reendothelialization in antineointima therapy after cardiovascular interventions. Drug-eluting stents are a common treatment for coronary artery diseases. However, drugs currently used in clinic, such as sirolimus and paclitaxel, have side effects, causing defective re-endothelialization and increasing risk of late thrombosis. 27 Our exciting finding is that blockade of CTPS1 function accelerates re-endothelialization in 2 injury models, which is likely because of the reduction of proliferating SMCs, as well as the induction of NME-mediated salvage pathways. Proliferative SMCs are known to produce various paracrine factors to inhibit EC proliferation. [28] [29] [30] Reduction of proliferating SMCs benefits re-endothelialization as long as EC proliferation is not inhibited, which can be achieved via the activation of CTP salvage pathway. Salvage pathway enzyme NME2 seems to be expressed at a relatively low level under normal EC growth condition. However, when CTPS activity is blocked by CPEC, NME2 is dramatically induced in ECs while neointima proliferating SMCs are significantly reduced. Although both NME1 and NME2 are important for CTP synthesis, NME2 seems to have a stronger capability in using cytidine. Indeed, knockdown of NME2 significantly diminishes EC proliferation in the presence of CPEC and cytidine. These results demonstrate that the salvage pathway is upregulated to compensate for CPEC-blocked CTP synthesis, which sustains the EC proliferation. The combined effect of blocking CTPS1 on inhibiting SMC proliferation while sustaining EC proliferation results in the accelerated re-endothelialization in EC-denuded vessels.
It is interesting that ECs, but not SMCs, use salvage pathways to synthesize CTP, which is likely because of the accessibility of ECs to the salvage pathway-specific substrate cytidine. Cytidine is circulating in the bloodstream, which consistently interacts with ECs. Therefore, ECs may adopt a unique mechanism by which cytidine is used to synthesize CTP even under normal growing or quiescent states. This specialized ability is obviously enhanced when the de novo pathway is impaired.
One limitation of this study is that the effect of the systematic blockade of CTPS on inflammatory cells, such as leukocyte infiltration or the differentiation of bone marrow-derived endothelial progenitor cells, is not studied. These cells are also involved in neointima formation and re-endothelialization in vivo, which may be investigated in the future. Nevertheless, our study discovered the divergent mechanisms in CTP synthesis between SMCs and ECs, which lays a foundation for developing SMC-sensitive therapeutics in preventing neointima formation while promoting re-endothelialization. Thus, targeting CTPS is likely to result in significantly improved vascular repair. In addition to CPEC, several other inhibitors, including 3-deazauridine, 31 carbodine, 32 and 6-diazo-5-oxonorleucine, 33 also effectively block CTPS activity, which further make CTPS a promising target in curing proliferative vascular diseases including those observed in cardiovascular interventions.
Drug-eluting stents are commonly used for treating coronary artery diseases. However, drugs currently used in clinics, such as sirolimus and paclitaxel, have side effects, causing defective re-endothelialization and increasing risk of late thrombosis because of their nonspecific effect on inhibiting proliferation of both smooth muscle and endothelial cells. Our study demonstrates for the first time that smooth muscle and endothelial cells have distinct preferences in using CTP synthesis pathways for their proliferation, which makes CTP synthase an ideal target for treating proliferative vascular diseases including those observed in cardiovascular interventions. The underlying mechanism is that blockade of CTP synthase induces CTP synthesis salvage pathway in endothelial cells, but not in smooth muscles, which sustains endothelial cell proliferation while blocking smooth muscle proliferation.
Significance
